Analysed BIOMEA FUSION INC (BMEA:NASDAQ) News Sources
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
31-03-2026
yahoo.com
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts
30-03-2026
marketbeat.com
Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes
30-03-2026
marketbeat.com
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results
25-03-2026
yahoo.com
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
24-03-2026
yahoo.com
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
14-03-2026
yahoo.com
Biomea Fusion Details Diabetes, Obesity Pipeline at Citizens Conference, Sees Cash Runway to Q1 2027
13-03-2026
marketbeat.com
Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf.
27-02-2026
marketbeat.com
What is the current price of BIOMEA FUSION INC (BMEA:NASDAQ)?
The current price of BIOMEA FUSION INC (BMEA:NASDAQ) is $1.87.
BIOMEA FUSION INC (BMEA:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIOMEA FUSION INC (BMEA:NASDAQ) since the previous trading day is $0.02.
BIOMEA FUSION INC (BMEA:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIOMEA FUSION INC (BMEA:NASDAQ) since the previous trading day is 1.0811%.
What is the most recent average sentiment score for BIOMEA FUSION INC (BMEA:NASDAQ)?
The most recent average sentiment score for BIOMEA FUSION INC (BMEA:NASDAQ) is 87 out of 100.
What is the most recent average sentiment for BIOMEA FUSION INC (BMEA:NASDAQ)?
The most recent sentiment for BIOMEA FUSION INC (BMEA:NASDAQ) is .
SEC-8K** Filing Available For BIOMEA FUSION INC (BMEA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.